CD274 and renal cell carcinoma: In this proof-of-concept study, we aimed to elucidate a possible role of PD-L1 as a liquid biomarker in the urine of patients with advanced RCC undergoing treatment as well as in treatment-naïve, i.e., pre-surgical, RCC patients.